Show Search Form

Search Results

human indexable	true false
published	true false
registered interest	true false
answer date	exactly: or between: and
date	exactly: or between: and
date tabled	exactly: or between: and
ddp created	exactly: or between: and
answering body
question status
answering dept id
answering dept short name
answering dept sort name
ddp modified
hansard heading
house id
identifier
legislature	pref label
parliament number
question first answered
question text
session
session number
tabling member printed
title
type
uin
version
written parliamentary question type
answer	is ministerial correction true false
creator	label
publisher	pref label
tabling member	label

Search

1006668

	human indexable
	published
	registered interest
	answer date	27/11/2018
	date	13/11/2018
	date tabled	13/11/2018
	ddp created	13/11/2018 21:55:22
	answering body	Department of Health and Social Care
	question status	Tabled
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	ddp modified	13/11/2018 22:05:35 27/11/2018 16:01:01
	hansard heading	Cancer: Screening
	house id	2
	identifier	HL11448
	legislature	25277 pref label House of Lords
	parliament number	57
	question first answered	27/11/2018 15:29:48
	question text	To ask Her Majesty's Government which cancers have been recommended by NICE for molecular testing; and of those cancers, for which biomarkers in relation to (1) prognostic tests, and (2) theranostic or treatment predictive tests.
	session	2017/19
	session number	1
	tabling member printed	Lord Freyberg
	title	House of Lords Tabled Parliamentary Question 2017/19 HL11448
	type	WrittenParliamentaryQuestion
	uin	HL11448
	version	1
	written parliamentary question type	Ordinary
	answer	answer is ministerial correction
	creator	2593 label Biography information for Lord Freyberg
	publisher	25277 pref label House of Lords
	tabling member	2593 label Biography information for Lord Freyberg

1006669

	human indexable
	published
	registered interest
	answer date	27/11/2018
	date	13/11/2018
	date tabled	13/11/2018
	ddp created	13/11/2018 21:55:23
	answering body	Department of Health and Social Care
	question status	Tabled
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	ddp modified	13/11/2018 22:05:37 27/11/2018 16:20:24
	hansard heading	Cancer: Screening
	house id	2
	identifier	HL11449
	legislature	25277 pref label House of Lords
	parliament number	57
	question first answered	27/11/2018 15:48:20
	question text	To ask Her Majesty's Government which NHS England trusts currently carry out cancer tests in compliance with NICE guidelines; and in relation to which cancers.
	session	2017/19
	session number	1
	tabling member printed	Lord Freyberg
	title	House of Lords Tabled Parliamentary Question 2017/19 HL11449
	type	WrittenParliamentaryQuestion
	uin	HL11449
	version	1
	written parliamentary question type	Ordinary
	answer	answer is ministerial correction
	creator	2593 label Biography information for Lord Freyberg
	publisher	25277 pref label House of Lords
	tabling member	2593 label Biography information for Lord Freyberg

1006670

	human indexable
	published
	registered interest
	answer date	27/11/2018
	date	13/11/2018
	date tabled	13/11/2018
	ddp created	13/11/2018 21:55:25
	answering body	Department of Health and Social Care
	question status	Tabled
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	ddp modified	13/11/2018 22:05:39 27/11/2018 16:20:22
	hansard heading	Cancer: Screening
	house id	2
	identifier	HL11450
	legislature	25277 pref label House of Lords
	parliament number	57
	question first answered	27/11/2018 15:48:20
	question text	To ask Her Majesty's Government which NHS England trusts, if any, have secured funding to test for cancers clinically beyond the NICE guidelines, including through use of theranostic tests and somatic gene panels that can report back to patients within a clinically actionable time frame; and in relation to which cancers.
	session	2017/19
	session number	1
	tabling member printed	Lord Freyberg
	title	House of Lords Tabled Parliamentary Question 2017/19 HL11450
	type	WrittenParliamentaryQuestion
	uin	HL11450
	version	1
	written parliamentary question type	Ordinary
	answer	answer is ministerial correction
	creator	2593 label Biography information for Lord Freyberg
	publisher	25277 pref label House of Lords
	tabling member	2593 label Biography information for Lord Freyberg

1006671

	human indexable
	published
	registered interest
	answer date	27/11/2018
	date	13/11/2018
	date tabled	13/11/2018
	ddp created	13/11/2018 21:55:26
	answering body	Department of Health and Social Care
	question status	Tabled
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	ddp modified	13/11/2018 22:05:40 27/11/2018 16:20:21
	hansard heading	Cancer: Screening
	house id	2
	identifier	HL11451
	legislature	25277 pref label House of Lords
	parliament number	57
	question first answered	27/11/2018 15:48:20
	question text	To ask Her Majesty's Government what assessment they have made of the main reasons for non-compliance with NICE guidelines for testing for cancer by NHS England trusts.
	session	2017/19
	session number	1
	tabling member printed	Lord Freyberg
	title	House of Lords Tabled Parliamentary Question 2017/19 HL11451
	type	WrittenParliamentaryQuestion
	uin	HL11451
	version	1
	written parliamentary question type	Ordinary
	answer	answer is ministerial correction
	creator	2593 label Biography information for Lord Freyberg
	publisher	25277 pref label House of Lords
	tabling member	2593 label Biography information for Lord Freyberg

1006672

	human indexable
	published
	registered interest
	answer date	27/11/2018
	date	13/11/2018
	date tabled	13/11/2018
	ddp created	13/11/2018 21:55:27
	answering body	Department of Health and Social Care
	question status	Tabled
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	ddp modified	13/11/2018 22:05:42 27/11/2018 16:20:02
	hansard heading	Cancer: Screening
	house id	2
	identifier	HL11452
	legislature	25277 pref label House of Lords
	parliament number	57
	question first answered	27/11/2018 15:48:42
	question text	To ask Her Majesty's Government what progress they have made towards the Cancer Task Force’s recommendation for a national molecular pathology service; and when they anticipate to implement this fully in relation to adult cancer diagnosis and care.
	session	2017/19
	session number	1
	tabling member printed	Lord Freyberg
	title	House of Lords Tabled Parliamentary Question 2017/19 HL11452
	type	WrittenParliamentaryQuestion
	uin	HL11452
	version	1
	written parliamentary question type	Ordinary
	answer	answer is ministerial correction
	creator	2593 label Biography information for Lord Freyberg
	publisher	25277 pref label House of Lords
	tabling member	2593 label Biography information for Lord Freyberg

1007501

	human indexable
	published
	registered interest
	answer date	28/11/2018
	date	14/11/2018
	date tabled	14/11/2018
	ddp created	14/11/2018 21:42:40
	answering body	Department of Health and Social Care
	question status	Tabled
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	ddp modified	14/11/2018 21:45:44 28/11/2018 15:22:04
	hansard heading	Cancer: Screening
	house id	2
	identifier	HL11501
	legislature	25277 pref label House of Lords
	parliament number	57
	question first answered	28/11/2018 14:50:06
	question text	To ask Her Majesty's Government what assessment they have made of (1) the economic importance of clinical trial recruitment, especially in cancer research, to the UK economy, and (2) the importance of timely molecular testing in modern cancer trial recruitment; and whether, as a result of any such assessment, NHS England will consider implementing national somatic gene testing in cancers with low survival rates to catalyse research.
	session	2017/19
	session number	1
	tabling member printed	Lord Freyberg
	title	House of Lords Tabled Parliamentary Question 2017/19 HL11501
	type	WrittenParliamentaryQuestion
	uin	HL11501
	version	1
	written parliamentary question type	Ordinary
	answer	answer is ministerial correction
	creator	2593 label Biography information for Lord Freyberg
	publisher	25277 pref label House of Lords
	tabling member	2593 label Biography information for Lord Freyberg

1007502

	human indexable
	published
	registered interest
	answer date	28/11/2018
	date	14/11/2018
	date tabled	14/11/2018
	ddp created	14/11/2018 21:42:41
	answering body	Department of Health and Social Care
	question status	Tabled
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	ddp modified	14/11/2018 21:45:46 28/11/2018 15:22:07
	hansard heading	Cancer: Screening
	house id	2
	identifier	HL11502
	legislature	25277 pref label House of Lords
	parliament number	57
	question first answered	28/11/2018 14:50:06
	question text	To ask Her Majesty's Government what assessment the Chief Scientific Adviser has made of the importance of molecular testing to drive modern cancer trial recruitment, and of the introduction of such testing for which cancers offer the most value to the UK in terms of driving clinical trial recruitment.
	session	2017/19
	session number	1
	tabling member printed	Lord Freyberg
	title	House of Lords Tabled Parliamentary Question 2017/19 HL11502
	type	WrittenParliamentaryQuestion
	uin	HL11502
	version	1
	written parliamentary question type	Ordinary
	answer	answer is ministerial correction
	creator	2593 label Biography information for Lord Freyberg
	publisher	25277 pref label House of Lords
	tabling member	2593 label Biography information for Lord Freyberg

1017055

	human indexable
	published
	registered interest
	answer date	12/12/2018
	date	28/11/2018
	date tabled	28/11/2018
	ddp created	28/11/2018 22:01:32
	answering body	Department of Health and Social Care
	question status	Tabled
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	ddp modified	28/11/2018 22:06:07 06/12/2018 15:20:05
	hansard heading	Cancer: Screening
	house id	2
	identifier	HL11900
	legislature	25277 pref label House of Lords
	parliament number	57
	question first answered	06/12/2018 14:46:02
	question text	To ask Her Majesty's Government, further to the Written Answer by Lord O'Shaughnessy on 27 November (HL11452), what was the average turnaround time from sample collection to clinical report for Genomic England's somatic whole genome sequencing for cancer patients in the last six months; what is the most clinically useful timeframe from sample collection to clinical report for such genome sequencing; and how many cancer patients in Genomic England's programme have died to date without receiving their clinical report.
	session	2017/19
	session number	1
	tabling member printed	Lord Freyberg
	title	House of Lords Tabled Parliamentary Question 2017/19 HL11900
	type	WrittenParliamentaryQuestion
	uin	HL11900
	version	1
	written parliamentary question type	Ordinary
	answer	answer is ministerial correction
	creator	2593 label Biography information for Lord Freyberg
	publisher	25277 pref label House of Lords
	tabling member	2593 label Biography information for Lord Freyberg

1017056

	human indexable
	published
	registered interest
	answer date	12/12/2018
	date	28/11/2018
	date tabled	28/11/2018
	ddp created	28/11/2018 22:01:33
	answering body	Department of Health and Social Care
	question status	Tabled
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	ddp modified	28/11/2018 22:06:09 06/12/2018 15:20:03
	hansard heading	Cancer: Screening
	house id	2
	identifier	HL11901
	legislature	25277 pref label House of Lords
	parliament number	57
	question first answered	06/12/2018 14:46:33
	question text	To ask Her Majesty's Government what economic modelling NHS England has carried out on the net budgetary impact of introducing a national molecular pathology service in cancer; what estimate they have made of the direct annual cost of such a service; whether they have considered switching off any legacy services to help fund its introduction; and if so, which.
	session	2017/19
	session number	1
	tabling member printed	Lord Freyberg
	title	House of Lords Tabled Parliamentary Question 2017/19 HL11901
	type	WrittenParliamentaryQuestion
	uin	HL11901
	version	1
	written parliamentary question type	Ordinary
	answer	answer is ministerial correction
	creator	2593 label Biography information for Lord Freyberg
	publisher	25277 pref label House of Lords
	tabling member	2593 label Biography information for Lord Freyberg

1050851

	human indexable
	published
	registered interest
	answer date	12/02/2019
	date	29/01/2019
	date tabled	29/01/2019
	ddp created	29/01/2019 21:21:48
	answering body	Department of Health and Social Care
	question status	Tabled
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	ddp modified	29/01/2019 21:28:18 12/02/2019 16:26:06
	hansard heading	Cancer: Screening
	house id	2
	identifier	HL13269
	legislature	25277 pref label House of Lords
	parliament number	57
	question first answered	12/02/2019 15:54:06
	question text	To ask Her Majesty's Government whether they intend to introduce national funding for cancer genomic testing in England; and if so, when.
	session	2017/19 (57)
	session number	1
	tabling member printed	Lord Warner
	title	House of Lords Tabled Parliamentary Question 2017/19 (57) HL13269
	type	WrittenParliamentaryQuestion
	uin	HL13269
	version	1
	written parliamentary question type	Ordinary
	answer	answer is ministerial correction
	creator	1732 label Biography information for Lord Warner
	publisher	25277 pref label House of Lords
	tabling member	1732 label Biography information for Lord Warner